Affiliations 

  • 1 Real-World Insights, IQVIA, Asia-Pacific, Singapore junice.ng@iqvia.com
  • 2 Real-World Insights, IQVIA, Asia-Pacific, Singapore
  • 3 Department of Pharmacology and Toxicology, University of the Philippines Manila College of Medicine, Manila, Metro Manila, Philippines
  • 4 Section of Endocrinology, Diabetes, Metabolism and Nutrition, Ospital Ng Makati, Makati, Metro Manila, Philippines
  • 5 Section of Endocrinology, Diabetes and Metabolism, St. Luke's Medical Center, Quezon City, Metro Manila, Philippines
  • 6 Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, National Capital Region, Philippines
  • 7 Department of Medicine, University of the East, Ramon Magasaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines
  • 8 Institute for Studies on Diabetes Foundation Inc, Marikina City, Metro Manila, Philippines
  • 9 Benefits Development and Research Department, Philippine Health Insurance Corporation, Manila, Metro Manila, Philippines
  • 10 Department of Health, Health Research Division, Health Policy Development and Planning Bureau, Manila, Metro Manila, Philippines
  • 11 Market Access, Health Economics, and Public Affairs, Novo Nordisk Region Southeast Asia, Kuala Lumpur, Malaysia
BMJ Open, 2020 07 28;10(7):e025696.
PMID: 32723733 DOI: 10.1136/bmjopen-2018-025696

Abstract

INTRODUCTION: Diabetes and its complications are a major cause of morbidity and mortality in the Philippines. The prevalence of diabetes in the Philippines has increased from 3.4 million in 2010 to 3.7 million in 2017. The government has formulated strategies to control this increase, for example, through its non-communicable disease prevention and control plan. However, there is scarce research on the financial burden of diabetes. Filling this gap may further help policymakers to make informed decisions while developing and implementing resource planning for relevant interventions. The primary objective of the current study is to estimate the direct medical costs associated with type 2 diabetes mellitus (T2DM).

METHODS AND ANALYSIS: This is a 1-year retrospective cohort study of patients with T2DM in 2016. Data will be collected from: (1) hospital databases from public institutions to estimate the cost of diabetes treatment and (2) physician interviews to estimate the cost of management of diabetes in outpatient care. We will perform descriptive and comparative analyses on direct medical costs and healthcare resource utilisation, stratified by the presence of diabetes-associated complications.

ETHICS AND DISSEMINATION: Research ethics board approval has been obtained from the Department of Health Single Joint Research Ethics Board and Cardinal Santos Medical Center Research Ethics Review Committee. Findings from the study will be reported in peer-reviewed scientific journals and local researcher meetings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications